It was determined that Isogarcinol confers a significant immunosuppressive effect on SLE (Chen et al., 2017), and works by regulating abnormal activation of CD4 T cells, which cause inflammation (Li et al., 2015). Here, CD4 is linked to systemic lupus erythematosus.